2023
Cost-effectiveness analysis of typhoid conjugate vaccines in an outbreak setting: a modeling study
Phillips M, Antillon M, Bilcke J, Bar-Zeev N, Limani F, Debellut F, Pecenka C, Neuzil K, Gordon M, Thindwa D, Paltiel A, Yaesoubi R, Pitzer V. Cost-effectiveness analysis of typhoid conjugate vaccines in an outbreak setting: a modeling study. BMC Infectious Diseases 2023, 23: 143. PMID: 36890448, PMCID: PMC9993384, DOI: 10.1186/s12879-023-08105-2.Peer-Reviewed Original ResearchConceptsTyphoid Conjugate VaccineRoutine vaccinationReactive vaccinationVaccination strategiesOutbreak settingsMultidrug-resistant Salmonella typhiQueen Elizabeth Central HospitalTyphoid fever epidemicYears of ageMonths of ageCost-effectiveness analysisWorld Health OrganizationConjugate vaccineCentral HospitalRoutine immunizationVaccine deploymentPreventive vaccinationVaccinationTyphoid feverCost-effective strategyAge 15Health OrganizationFever epidemicAntimicrobial resistanceOutbreak definitions
2019
Predicting the Impact of Typhoid Conjugate Vaccines on Antimicrobial Resistance
Kaufhold S, Yaesoubi R, Pitzer VE. Predicting the Impact of Typhoid Conjugate Vaccines on Antimicrobial Resistance. Clinical Infectious Diseases 2019, 68: s96-s104. PMID: 30845324, PMCID: PMC6405272, DOI: 10.1093/cid/ciy1108.Peer-Reviewed Original ResearchConceptsChronic carriersAntimicrobial-resistant infectionsProportion of casesTyphoid-endemic settingsTyphoid infectionVaccination coverageResistant infectionsFuture vaccination campaignsOne-way sensitivity analysesTyphoid Conjugate VaccineTransmission dynamic modelSalmonella enterica serovar TyphiEmpiric prescribingConjugate vaccineEnterica serovar TyphiIntroduction of typhoidTreatment strategiesVaccination campaignTotal casesHealth outcomesNumber of casesRate of recoveryInfectionResistant strainsTotal number